Class information for:
Level 1: NIMOTUZUMAB//H R3//CETUXIMAB

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
4614 1682 49.3 85%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
451 15419 HER 2//TRASTUZUMAB//LAPATINIB

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 NIMOTUZUMAB Author keyword 51 63% 3% 52
2 H R3 Author keyword 23 86% 1% 12
3 CETUXIMAB Author keyword 23 12% 10% 176
4 ZD1839 Author keyword 15 44% 2% 27
5 RADIOBIOL MOL ENVIRONM Address 11 43% 1% 20
6 C225 Author keyword 9 45% 1% 15
7 TUMOR BIOL METASTASIS GRP Address 9 83% 0% 5
8 OSI 774 Author keyword 7 53% 1% 9
9 ZALUTUMUMAB Author keyword 6 80% 0% 4
10 ZD1839 IRESSA TM Author keyword 6 80% 0% 4

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 NIMOTUZUMAB 51 63% 3% 52 Search NIMOTUZUMAB Search NIMOTUZUMAB
2 H R3 23 86% 1% 12 Search H+R3 Search H+R3
3 CETUXIMAB 23 12% 10% 176 Search CETUXIMAB Search CETUXIMAB
4 ZD1839 15 44% 2% 27 Search ZD1839 Search ZD1839
5 C225 9 45% 1% 15 Search C225 Search C225
6 OSI 774 7 53% 1% 9 Search OSI+774 Search OSI+774
7 ZALUTUMUMAB 6 80% 0% 4 Search ZALUTUMUMAB Search ZALUTUMUMAB
8 ZD1839 IRESSA TM 6 80% 0% 4 Search ZD1839+IRESSA+TM Search ZD1839+IRESSA+TM
9 IMC C225 6 58% 0% 7 Search IMC+C225 Search IMC+C225
10 EGFR INHIBITION 5 32% 1% 12 Search EGFR+INHIBITION Search EGFR+INHIBITION

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ZD1839 IRESSA 68 33% 10% 170
2 C225 46 64% 3% 45
3 PLUS CETUXIMAB 41 32% 6% 107
4 H R3 31 92% 1% 12
5 HUMAN PANCREATIC CARCINOMA 20 37% 3% 44
6 ANTIBODY CETUXIMAB 17 42% 2% 32
7 MONOCLONAL ANTIBODY H R3 17 68% 1% 15
8 MONOCLONAL ANTIBODY C225 15 71% 1% 12
9 MONOCLONAL ANTIBODY CETUXIMAB 11 43% 1% 20
10 ZD 1839 IRESSA 10 43% 1% 18

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Review of epidermal growth factor receptor biology 2004 358 46 52%
A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor 2001 634 55 62%
Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC) 2014 15 83 46%
Epidermal growth factor receptor targeting in cancer 2006 344 141 36%
Understanding resistance to EGFR inhibitors-impact on future treatment strategies 2010 234 164 21%
HER2 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma 2015 1 57 46%
Targeting the EGFR signaling pathway in cancer therapy 2012 73 133 22%
Biology of interactions: Antiepidermal growth factor receptor agents 2007 126 92 52%
Epidermal growth factor receptor inhibition strategies in oncology 2004 175 72 65%
Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer 2008 142 70 36%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 RADIOBIOL MOL ENVIRONM 11 43% 1.2% 20
2 TUMOR BIOL METASTASIS GRP 9 83% 0.3% 5
3 ONCOPHARMACOL UNIT 6 24% 1.3% 22
4 CATTEDRA ONCOL MED 3 13% 1.4% 24
5 TUMOUR BIOL METASTASIS GRP 3 100% 0.2% 3
6 ONCORAY ZENTRUM STRAHLENFOR ONKOL 3 60% 0.2% 3
7 DIPARTIMENTO ENDOCRINOL ONCOL MOL CLIN 2 10% 1.4% 23
8 MCELWAIN S 2 24% 0.5% 9
9 EA3836 2 44% 0.2% 4
10 TUMOUR BIOL METASTASIS TEAM 2 44% 0.2% 4

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000147965 HER3//NUCLEAR EGFR//EGFR FAMILY
2 0.0000138480 BREAST CARCINOMA CELL LINE//BIOTINYLATED EPIDERMAL GROWTH FACTOR//BREAST CANCER BIOPSIES
3 0.0000135079 GEFITINIB//ERLOTINIB//EGFR MUTATION
4 0.0000130599 EGF POLYMORPHISM//GEFITINIB THERAPY//INTRON 1 POLYMORPHISM
5 0.0000130279 ANILINOQUINAZOLINE//COMBI MOLECULE//CANC DRUG
6 0.0000123918 BIOMARKERS BRANCH//CLONOGEN//COLORADO PARTY
7 0.0000121160 HUMAN MALIGNANT GLIOMAS//MOL EXPT RADIOL//RADGENOM GRP
8 0.0000121120 OSI 420//OSI 774//CAKI 1 RENAL CELL CARCINOMA
9 0.0000118841 PANITUMUMAB//CETUXIMAB//METASTATIC COLORECTAL CANCER
10 0.0000117231 EBP1//RADIOBIOL CANC//PA2G4